Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Heron Therapeutics Inc (HRTX) vs TeraWulf Inc (WULF) Price & Performance

Heron Therapeutics IncTrade
TeraWulf IncTrade

Price performance (Past 24H)

Key statistics

Heron Therapeutics Inc vs TeraWulf Inc — how do they compare? Heron Therapeutics Inc trades at $0.32 (market cap $63.41M), while TeraWulf Inc trades at $17.3 (market cap $8.08B). The key difference: TeraWulf Inc is far larger — about 127.4× Heron Therapeutics Inc's market cap, and TeraWulf Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.

HRTXWULF
Market Cap
$63.41M$8.08B
Sector
HealthTechnology
52-Week High
$1.49$28.98
52-Week Low
$0.32$5.24
Enterprise Value
$161.31M$10.70B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Heron Therapeutics Inc

Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.

HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.

TeraWulf Inc

TeraWulf (WULF) trades at $17.08, down 3.04% on the day, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $165M but a significant net loss of -$1.9B, reflecting a profit margin of -1,179.95%. Despite negative profitability metrics, all 14 analysts maintain Buy ratings with a $38 consensus price target, citing growth potential from AI infrastructure expansion including a major Anthropic lease.

The stock presents a high-risk, high-reward opportunity with strong Wall Street conviction despite fundamental challenges. Key catalysts include the AI pivot and capacity expansion, but investors face substantial execution risks, capital requirements, and ongoing losses that could pressure the stock near-term.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX

About TeraWulf Inc

TeraWulf develops, owns, and operates fully integrated digital infrastructure powered by predominantly zero-carbon energy. It utilizes a hybrid business model that combines industrial-scale Bitcoin mining with high-performance computing (HPC) and AI hosting, leveraging sustainable power sources like nuclear and hydroelectric to deliver low-cost, energy-efficient data center solutions.

Read more on WULF